Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 12/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.67 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065229 | 1.00 | MCHR1 (0.67) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4252556 | 0.88 | MCHR1 (0.64) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4076079 | 0.88 | MCHR1 (0.64) | MCHR1KCNH2AVPR1A | |
| SCHEMBL13664933 | 0.86 | MCHR1 (0.63) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4069998 | 0.85 | MCHR1 (0.57) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4320203 | 0.85 | MCHR1 (0.57) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4066616 | 0.84 | MCHR1 (0.61) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4078212 | 0.84 | MCHR1 (0.61) | MCHR1KCNH2AVPR1A | |
| SCHEMBL13664937 | 0.81 | MCHR1 (0.65) | MCHR1KCNH2AVPR1A | |
| SCHEMBL4069162 | 0.81 | MCHR1 (0.67) | MCHR1KCNH2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | MCHR1 730/4885KCNH2 296/4885AVPR1A 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.